Trial for cancer drug rash relief withdrawn before starting
NCT ID NCT04731259
Summary
This study aimed to test the safety of an investigational product called ATR-04 for reducing the severity of a painful, acne-like facial rash that is a common side effect of certain cancer drugs. It planned to enroll about 60 adults with cancer who were starting these specific drug treatments. The trial was designed to compare ATR-04 against a placebo over 28 days of treatment, but it was withdrawn before any participants were enrolled.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPIDERMAL GROWTH FACTOR are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.